{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","estimateComment":"Hazard ratios (HRs) were estimated using a Pike estimator.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.81"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"38.2","value":"25.8"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"23.1","value":"18.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"212"}],"units":"Participants"}],"description":"OS is defined as the interval of time between the date of randomization and the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 milligram (mg) HPMC capsules orally twice daily (BID), once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib 2 mg once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib + Trametinib"},{"description":"Participants received dabrafenib 150 mg HPMC capsules orally BID, once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib placebo once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Crossover to the combination therapy arm was allowed for subjects still receiving study treatment on the dabrafenib monotherapy arm after the positive result for the final OS analysis.","id":"OG001","title":"Dabrafenib + Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population was considered.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until date of death due to any cause (up to approximately 6 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}